Article source：Kexing Biopharm
Nov 03,2025
View：
96 In the ever-evolving landscape of biologic treatments, Kexing Biopharm has made a significant stride with the introduction of Reminton, the first infliximab biosimilar to be marketed in China. This milestone marks a new era in the treatment of various autoimmune and inflammatory diseases, offering patients a more accessible and cost-effective alternative to the original infliximab. In this blog post, we will delve into the details of this innovative biosimilar, its clinical benefits, and its implications for the future of biologic therapy.
Kexing Biopharm’s licensed-in Reminton from Mabpharm Limited. Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from an FDA-approved reference product. The journey to creating a biosimilar involves a rigorous process of research, development, and clinical trials to ensure that the biosimilar is as effective and safe as the original biologic.
One of the key factors that sets Reminton apart is its production using the CHO (Chinese Hamster Ovary) cell expression system. This system is widely recognized for its ability to produce high-quality proteins with consistent characteristics. The use of CHO cells in the production of Reminton has resulted in a biosimilar with good efficacy, better safety, and lower immunogenicity, as demonstrated in clinical studies. This is a significant achievement, as it ensures that patients receive a product that is not only effective but also has a reduced risk of adverse reactions.
The clinical studies conducted on Reminton have shown promising results, proving its efficacy in treating a range of conditions. As an infliximab biosimilar, Reminton has been tested against the stringent standards of the original infliximab, ensuring that it meets the same high bar for effectiveness and safety. The studies have shown that Reminton is effective in treating Crohn's disease in adults and children over 6 years of age, including those with moderate to severe, active disease, as well as those with fistulizing Crohn's disease. Additionally, it has been proven effective in treating ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Crohn's disease is a chronic inflammatory bowel disease that can be debilitating and difficult to manage. The introduction of Reminton as an infliximab biosimilar expands the treatment options for patients suffering from this condition. It offers a viable alternative for those who may not respond well to other treatments or who are seeking a more cost-effective option. The fact that Reminton has been shown to be effective in both adults and children over 6 years of age is a significant advancement, as it provides a broader patient population with access to this life-changing therapy.
Ulcerative colitis is another inflammatory bowel disease that can severely impact a patient's quality of life. Reminton's approval for use in adults with ulcerative colitis is a significant development in the treatment landscape. As an infliximab biosimilar, Reminton offers the same efficacy as the original infliximab, providing patients with a new option for managing their symptoms and improving their overall well-being.
Ankylosing spondylitis and rheumatoid arthritis are both chronic conditions that cause inflammation in the joints, leading to pain and stiffness. The approval of Reminton for these indications is a welcome addition to the treatment arsenal for patients suffering from these diseases. As an infliximab biosimilar, Reminton has the potential to provide the same level of relief and improvement in quality of life as the original infliximab, but at a potentially lower cost.
Psoriasis is a chronic skin condition characterized by red, scaly patches on the skin. The approval of Reminton for the treatment of psoriasis is a significant step forward in the management of this condition. As an infliximab biosimilar, Reminton offers patients a new option for treating their symptoms and improving their skin health.
The introduction of Reminton, Kexing Biopharm's infliximab biosimilar, it signifies a shift towards more accessible and affordable treatments for patients suffering from autoimmune and inflammatory diseases. As the first infliximab biosimilar marketed in China, Reminton sets a precedent for future biosimilars, paving the way for increased competition and potentially lower prices for biologic drugs.
BACK TO LIST
Aug 12,2025
